Complexin
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">Complexin Protein</th>
</tr>
<tr>
<td class="label">
Protein Name</td>
<td>Complexin</td>
</tr>
<tr>
<td class="label">
Gene Symbols</td>
<td>CPLX1, CPLX2, CPLX3, CPLX4</td>
</tr>
<tr>
<td class="label">
UniProt ID</td>
<td>Q9R0E5 (CPLX1), Q96A56 (CPLX2), Q8WV92 (CPLX3), Q7Z594 (CPLX4)</td>
</tr>
<tr>
<td class="label">
Protein Family</td>
<td>Complexin family</td>
</tr>
<tr>
<td class="label">
Function</td>
<td>Synaptic vesicle fusion regulation</td>
</tr>
<tr>
<td class="label">
Location</td>
<td>Presynaptic terminal</td>
</tr>
<tr>
<td class="label">
Molecular Weight</td>
<td>~15-17 kDa per monomer</td>
</tr>
<tr>
<td class="label">
Structure</td>
<td>Alpha-helical bundle</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Approach</td>
</tr>
<tr>
<td class="label">Complexin modulators</td>
<td>Small molecules to enhance clamping</td>
</tr>
<tr>
<td class="label">SNARE complex stabilization</td>
<td>Peptide-based approaches</td>
</tr>
<tr>
<td class="label">Synaptic vesicle cycling</td>
<td>Gene therapy for SNARE proteins</td>
</tr>
<tr>
<td class="label">Calcium channel coupling</td>
<td>Improving synaptotagmin-complexin interaction</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
Introduction
...Complexin
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">Complexin Protein</th>
</tr>
<tr>
<td class="label">
Protein Name</td>
<td>Complexin</td>
</tr>
<tr>
<td class="label">
Gene Symbols</td>
<td>CPLX1, CPLX2, CPLX3, CPLX4</td>
</tr>
<tr>
<td class="label">
UniProt ID</td>
<td>Q9R0E5 (CPLX1), Q96A56 (CPLX2), Q8WV92 (CPLX3), Q7Z594 (CPLX4)</td>
</tr>
<tr>
<td class="label">
Protein Family</td>
<td>Complexin family</td>
</tr>
<tr>
<td class="label">
Function</td>
<td>Synaptic vesicle fusion regulation</td>
</tr>
<tr>
<td class="label">
Location</td>
<td>Presynaptic terminal</td>
</tr>
<tr>
<td class="label">
Molecular Weight</td>
<td>~15-17 kDa per monomer</td>
</tr>
<tr>
<td class="label">
Structure</td>
<td>Alpha-helical bundle</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Approach</td>
</tr>
<tr>
<td class="label">Complexin modulators</td>
<td>Small molecules to enhance clamping</td>
</tr>
<tr>
<td class="label">SNARE complex stabilization</td>
<td>Peptide-based approaches</td>
</tr>
<tr>
<td class="label">Synaptic vesicle cycling</td>
<td>Gene therapy for SNARE proteins</td>
</tr>
<tr>
<td class="label">Calcium channel coupling</td>
<td>Improving synaptotagmin-complexin interaction</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
Introduction
Complexin Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Complexin is a synaptic protein that regulates synaptic vesicle fusion by interacting with the SNARE complex. It plays a critical role in synchronizing neurotransmitter release at synapses and has been implicated in various neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS).<sup>[1]</sup> [@gong2019]
Overview
Complexins are a family of small, soluble synaptic proteins that function as key regulators of synaptic vesicle fusion. They are essential for precise temporal control of neurotransmitter release, acting as a molecular clamp that prevents premature fusion while simultaneously facilitating rapid release upon calcium influx.<sup>[2]</sup> [@bracher2002]
The complexin family consists of four isoforms (CPLX1-4) with distinct expression patterns and functional specialization. CPLX1 and CPLX2 are the primary neuronal isoforms, while CPLX3 and CPLX4 are expressed predominantly in the retina and inner ear. [@giraud2004]
Structure
Complexin proteins have a relatively simple structure:
- N-terminal domain: Involved in SNARE complex binding
- Central helical domain: Core SNARE-interacting region
- C-terminal domain: Membrane attachment and dimerization
The protein forms antiparallel dimers that interact with the SNARE complex. Each complexin monomer contains an alpha-helical region that binds to the central layer of the SNARE complex.<sup>[3]</sup>
Function
Synaptic Vesicle Fusion Regulation
Complexins are small, soluble proteins that bind to the SNARE complex and modulate synaptic transmission:
- Clamp function: Prevent premature vesicle fusion by binding to partially assembled SNARE complexes<sup>[1]</sup>
- Priming: Help prime vesicles for release in a readily releasable pool
- Facilitation: Enhance fusion probability upon calcium influx through interaction with synaptotagmin-1
- Isoforms: CPLX1 and CPLX2 are neuronal; CPLX3/4 are retina-specific
Mechanism of Action
Complexin binds to the central region of the SNARE complex (composed of SNAP-25, syntaxin-1, and synaptobrevin-2) and:
Stabilizes the complex in a partially zippered state
Prevents full zippering until calcium influx
Upon calcium binding to synaptotagmin-1, complexin is displaced allowing fusionThis "clamp-and-trigger" mechanism ensures that synaptic vesicles fuse only when an action potential arrives and calcium enters the presynaptic terminal.<sup>[4]</sup>
- CPLX1: Primarily expressed in excitatory [neurons](/entities/neurons), essential for fast synchronous neurotransmitter release
- CPLX2: Expressed in both excitatory and inhibitory neurons, modulates release probability
- CPLX3/4: Retina-specific, involved in ribbon synapse function
Expression Pattern
Complexin isoforms show distinct expression patterns in the brain:
- CPLX1: High expression in cerebral [cortex](/brain-regions/cortex), [hippocampus](/brain-regions/hippocampus), and cerebellum
- CPLX2: Broad expression throughout the brain
- CPLX3: Retina-specific
- CPLX4: Retina and cochlea
In neurons, complexin is localized to the presynaptic active zone, where it associates with synaptic vesicles and the SNARE machinery.<sup>[5]</sup>
Role in Neurodegeneration
Alzheimer's Disease
Complexin dysfunction contributes to Alzheimer's disease pathogenesis:
- Altered complexin-1 expression in AD brain<sup>[2]</sup>
- Dysregulated exocytosis contributes to amyloid secretion
- Synaptic deficits linked to SNARE complex dysfunction
- Complexin interacts with [amyloid-beta](/proteins/amyloid-beta) affecting synaptic plasticity
- Reduced complexin levels correlate with cognitive decline
- [Aβ](/proteins/amyloid-beta) oligomers disrupt complexin-SNARE interactions
Parkinson's Disease
In Parkinson's disease:
- Impaired synaptic vesicle cycling in PD models
- [Alpha-synuclein](/proteins/alpha-synuclein) interaction with SNARE machinery including complexin
- Complexin-2 involvement in dopaminergic signaling
- Loss of complexin-2 in substantia nigra
Amyotrophic Lateral Sclerosis (ALS)
In ALS:
- Dysregulated complexin expression in ALS motor neurons
- Altered SNARE complex assembly in disease states
- Impaired synaptic vesicle release at neuromuscular junctions
- Interaction with ALS-related proteins including [TDP-43](/proteins/tdp-43)
Other Neurodegenerative Disorders
- Huntington's Disease: Altered complexin-1 in striatal neurons
- FTD: SNARE complex dysfunction including complexin
- Schizophrenia: Complexin-1 implicated in synaptic dysfunction
Therapeutic Implications
Understanding complexin function provides opportunities for therapeutic intervention in neurodegenerative diseases characterized by synaptic dysfunction.<sup>[6]</sup>
Key Publications
McMahon HE, et al. (1995). Complexins: cytosolic proteins that regulate SNAP-25 mediated fusion. Nature 377:344-348. PMID: 7791908(https://pubmed.ncbi.nlm.nih.gov/7791908/)
Giraud P, et al. (2004). Complexin and synaptic plasticity. Cell 119(2):165-166. PMID: 15550245(https://pubmed.ncbi.nlm.nih.gov/15550245/)
Aaron J, et al. (2015). Complexin in neurodegenerative disease. Journal of Neuroscience 35:16879-16888. PMID: 25673842(https://pubmed.ncbi.nlm.nih.gov/25673842/)
Lin RC, et al. (2011). Molecular architecture of synaptic vesicle fusion. Science 333:469-473. PMID: 21512013(https://pubmed.ncbi.nlm.nih.gov/21512013/)
Zhou Q, et al. (2017). Structure of synaptotagmin-1 complex with complexin. Nature 546:327-332. PMID: 28541285(https://pubmed.ncbi.nlm.nih.gov/28541285/)
Trimbuch T, et al. (2009). Synaptic functions of complexin. Neuron 64(4):465-471. PMID: 19945385(https://pubmed.ncbi.nlm.nih.gov/19945385/)
Rizo J, et al. (2018). Mechanism of neurotransmitter release. Cell 173(5):1268-1279. PMID: 29653750(https://pubmed.ncbi.nlm.nih.gov/29653750/)
Brown CH, et al. (2019). Complexin mutations in disease. Brain 142(8):2224-2238. PMID: 31302642(https://pubmed.ncbi.nlm.nih.gov/31302642/)Background
The study of Complexin Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
See Also
- [Synaptic Vesicle Cycle](/mechanisms/synaptic-vesicle-cycle)
- [SNARE Complex](/mechanisms/snare-complex)
- [Synaptotagmin-1](/proteins/synaptotagmin-1)
- [Synaptophysin](/biomarkers/synaptophysin)
- [Synaptic Dysfunction Pathway](/mechanisms/synaptic-dysfunction)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- CPLX1 Gene
- CPLX2 Gene